Virtual access to Extraordinary General Meeting 29 Dec 2023
Released
Released
Announcement PDF
Virtual access to Extraordinary General Meeting 29 December 2023
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 7 December 2023: Alterity Therapeutics
Limited (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company
dedicated to developing disease modifying treatments for neurodegenerative diseases, has
scheduled an Extraordinary General Meeting (Meeting) for shareholders on Friday 29 December
2023.
Further to the Notice of Meeting issued on 30 November 2023, in addition to the in-person
Meeting venue at Level 3, 62 Lygon Street, Carlton, Victoria 3053, Alterity will provide virtual
access for shareholders and proxy holders to be able to participate including to listen, ask
questions and vote at the Meeting.
Shareholders will be sent a personalised notification of the following options for participating in
the meeting shortly.
Attending the Meeting virtually
To watch the webcast, ask questions and vote on the day of the meeting, please visit:
https://meetnow.global/MHAMSP4
For instructions refer to the online user guide at
www.computershare.com.au/virtualmeetingguide
Attending the Meeting in person
The meeting will be held at Level 3, 62 Lygon Street, Carlton, Victoria 3053.
Voting before the Meeting
Shareholders are strongly encouraged to vote by lodging a directed proxy appointing the
Chairman before 10:00 am (AEDT) Wednesday 27 December 2023. Instructions for lodging
proxies are included on your personalised proxy form issued on 30 November 2023, or in the link
that you received if you provided an email address. Alternatively, you are able to vote ahead of
the Meeting via www.investorvote.com.au/Login using the control number of 133513.
About Alterity Therapeutics Limited
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate
future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has
the potential to treat various Parkinsonian disorders and is currently being evaluated in two
Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery
platform generating patentable chemical compounds to treat the underlying pathology of
neurological diseases. The Company is based in Melbourne, Australia, and San Francisco,
California, USA. For further information please visit the Company’s website at
www.alteritytherapeutics.com.
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.
Investor and Media Contacts:
Australia
Hannah Howlett
we-aualteritytherapeutics@we-worldwide.com
+61 450 648 064
U.S.
Remy Bernarda
remy.bernarda@iradvisory.com
+1 (415) 203-6386
Share your feedback
Discover